DPP4 and neoplasm: The currently known mechanism of sitagliptin‐mediated tumor suppression mainly involves the function of sitagliptin as a DPP4 inhibitor, which can inhibit epithelial‐mesenchymal transition and tumor metastasis by inhibiting DPP4 expression, thereby improving tumor immunity and immunotherapy.29